Home/Kyverna Therapeutics/Dominik Rüttinger, MD, MSc
DR

Dominik Rüttinger, MD, MSc

Chief Medical Officer

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical